Top Page
Orthocell Ltd
(Sydney:OCC)
Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)
Orthocell Ltd Business Overview & Revenue Model
Orthocell Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.40M | 7.55M | 5.32M | 4.24M | 1.53M | 1.02M |
| Gross Profit | 3.58M | 4.80M | 3.69M | 3.06M | 832.52K | 299.88K |
| EBITDA | -11.77M | -13.43M | -11.68M | -10.34M | -11.52M | -11.67M |
| Net Income | -8.57M | -8.57M | -7.18M | -6.25M | -9.11M | -9.04M |
Balance Sheet | ||||||
| Total Assets | 35.24M | 35.24M | 26.62M | 29.61M | 37.90M | 19.33M |
| Cash, Cash Equivalents and Short-Term Investments | 28.62M | 28.62M | 20.61M | 24.82M | 11.02M | 16.33M |
| Total Debt | 576.89K | 576.89K | 689.69K | 562.30K | 507.56K | 621.72K |
| Total Liabilities | 20.67M | 20.67M | 22.08M | 23.46M | 27.99M | 2.46M |
| Stockholders Equity | 14.57M | 14.57M | 4.53M | 6.15M | 9.90M | 16.87M |
Cash Flow | ||||||
| Free Cash Flow | -8.94M | -9.04M | -7.45M | 13.96M | -6.80M | -4.82M |
| Operating Cash Flow | -8.68M | -8.68M | -6.51M | 14.59M | -6.26M | -4.63M |
| Investing Cash Flow | -359.06K | -359.06K | -942.02K | -631.56K | -535.02K | -188.52K |
| Financing Cash Flow | 17.05M | 17.05M | 3.24M | -164.61K | 1.49M | 709.15K |
Orthocell Ltd Technical Analysis
Orthocell Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$582.12M | -9.48 | -35.86% | ― | ― | -19.21% | |
47 Neutral | AU$336.22M | -25.63 | -83.97% | ― | 1271.12% | 36.87% | |
44 Neutral | AU$172.06M | -6.77 | ― | ― | ― | 0.66% | |
41 Neutral | AU$290.07M | -29.11 | -89.70% | ― | 42.05% | -0.84% | |
40 Underperform | AU$137.13M | -6.44 | -81.03% | ― | -20.79% | 73.98% | |
40 Underperform | AU$91.29M | -11.47 | -47.98% | ― | 700.00% | 26.88% |
Orthocell Ltd Corporate Events
Orthocell Ltd has announced a change in the director’s interest, specifically regarding Paul Anderson, who has been issued 52,078 Short-Term Performance Rights following shareholder approval. This adjustment in director’s interest reflects the company’s ongoing commitment to aligning management incentives with shareholder interests, potentially impacting the company’s governance and stakeholder confidence.
Orthocell Limited announced the issuance of 52,078 performance rights set to expire in November 2028, as part of an employee incentive scheme. This move is aimed at motivating and retaining talent within the company, potentially enhancing its operational capabilities and competitive positioning in the biotechnology sector.
Orthocell Ltd has announced the increasing adoption of its product, Remplir™, among Australian urologists for nerve-sparing prostate cancer surgeries, with approximately 100 surgeries conducted nationwide. This application aims to reduce complications such as erectile dysfunction and urinary incontinence, presenting a significant commercial opportunity for the company. Orthocell plans to expand its U.S. market from $1.6 billion to $2 billion by investing in further research and establishing a commercialization advisory board to support a targeted U.S. launch. The company is also compiling clinical data from initial procedures in Australia to bolster its scientific foundation for international market launches.
Orthocell Limited has issued 230,770 fully paid ordinary shares at $1.30 each as part of a capital raising initiative. This move aligns with their strategy to enhance financial resources for ongoing product development and market expansion, potentially strengthening their position in the regenerative medicine industry.
Orthocell Ltd has announced the quotation of 230,770 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 14, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the visibility and accessibility of its securities.
Orthocell Limited announced the successful outcomes of its Annual General Meeting, where all resolutions, including a special resolution to amend the Constitution, were passed. This development signifies strong shareholder support and may enhance the company’s governance framework, potentially impacting its strategic direction and stakeholder relations positively.
Orthocell Limited held its Annual General Meeting where the Chair and Managing Director addressed stakeholders. The company continues to expand its market presence with recent product approvals and initial sales in the US, enhancing its position in the regenerative medicine industry. This growth is supported by a network of specialist distributors and ongoing development of its tendon cell therapy in the US.
Orthocell Ltd has expanded its distribution network in Canada by appointing a second distributor for its nerve repair device, Remplir™, achieving full national coverage in the US$75 million Canadian market. This strategic move enhances Orthocell’s market penetration, with first sales expected this quarter following a successful launch at a major medical conference. The new distributor, based in Ontario, will cover provinces outside Alberta and British Columbia, leveraging extensive experience in the nerve, spine, and orthopedic sectors. This expansion is part of Orthocell’s broader strategy to drive sales and establish strong distributor relationships globally, supported by a robust financial position and existing marketing and education teams.
Orthocell Ltd has successfully completed the first surgical case using its Remplir™ nerve repair device in Hong Kong, marking a significant milestone in its Asia-Pacific commercialization strategy. The launch at the Hong Kong Orthopaedic Association’s Annual Congress, in partnership with local distributor MontsMed, positions Orthocell to penetrate the Greater Bay Area market, a region with substantial growth potential. With a strong financial position and strategic partnerships, Orthocell is poised to expand its global footprint and increase revenue, with upcoming sales in Canada and Thailand and continued momentum in the US market.
Orthocell Ltd announced a change in the director’s interest, with Michael McNulty acquiring 24,561 ordinary shares through an on-market purchase. This transaction reflects a strategic move by the director to increase his stake in the company, potentially signaling confidence in Orthocell’s future growth and market positioning.
Orthocell Ltd has appointed MontsMed as the exclusive distributor for its Remplir product in Hong Kong, marking a significant step in its Asian commercialization strategy. This move is expected to facilitate market access in the Guangdong-Hong Kong-Macao Greater Bay Area, a region with a population of around 100 million, and complements ongoing sales efforts in Singapore and anticipated market entry in Thailand. The company’s strategic expansion is supported by a robust financial position and the recent appointment of a Commercial Director to oversee operations in Asia.
Orthocell Ltd has announced the issuance of unquoted equity securities, specifically options expiring in 2028, as part of a previously disclosed transaction. This strategic move could potentially enhance the company’s financial flexibility and support its ongoing initiatives in the regenerative medicine sector, impacting its market positioning and stakeholder interests.
Orthocell Limited has issued 22,846,154 fully paid ordinary shares at $1.30 each as part of a capital raising initiative. This move aligns with the company’s strategic efforts to enhance its financial standing and support ongoing negotiations with Hong Kong distributors. The issuance was conducted without disclosure to investors under specific provisions of the Corporations Act, indicating compliance with regulatory requirements. This capital injection is expected to bolster Orthocell’s operations and potentially strengthen its position in the regenerative medicine industry.
Orthocell Ltd has announced the quotation of 22,846,154 new ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 24, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s capital structure and market presence, which could have significant implications for its stakeholders and industry positioning.
Orthocell Limited has issued 150,000 fully paid ordinary shares at $0.48 each following the exercise of unlisted options, complying with relevant sections of the Corporations Act 2001. This issuance reflects the company’s ongoing efforts to strengthen its financial position and support its operations in the regenerative medicine sector, potentially impacting its market presence and stakeholder interests.
Orthocell Ltd has announced the application for quotation of 150,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing growth initiatives, potentially impacting its market positioning and offering new opportunities for stakeholders.
Orthocell Limited has increased its equity stake in Marine Biomedical Pty Ltd to 12%, securing global distribution rights for PearlBone™, an innovative bone substitute made from sustainably sourced pearl shells. This strategic investment enhances Orthocell’s regenerative medicine portfolio and positions the company to capitalize on the US$1.6 billion bone substitute market, with expectations of significant value growth following regulatory approvals.
Orthocell Ltd has issued a supplementary notice for its upcoming Annual General Meeting, scheduled for November 6, 2025. This notice includes additional resolutions, specifically the issuance of short-term performance rights to Mr. Paul Anderson or his nominees. Shareholders are advised to review this supplementary notice alongside the original notice to understand the new resolutions and their implications. The meeting will be held both in-person and online, and shareholders are encouraged to update their proxy votes if they wish to vote on the newly introduced resolutions.
Orthocell Ltd has announced a proposed issue of securities, including options and ordinary shares, set to be issued on October 24, 2025. This move is likely aimed at raising capital to support the company’s ongoing projects and strategic initiatives, potentially strengthening its position in the regenerative medicine market and providing opportunities for growth and development.
Orthocell Limited has successfully raised $30 million through an institutional placement, attracting significant interest from US and international investors. The funds will be used to accelerate the US rollout of Remplir, expand manufacturing capacity, and advance clinical studies for its use in prostate cancer surgeries. The company is also investing in new regenerative medicine applications, positioning itself strongly in the global market with over $50 million in cash and no debt. This strategic financial move is expected to enhance Orthocell’s market position and drive growth, particularly in the US, where the company has already achieved significant milestones in its commercial operations.
Orthocell Limited, a company listed on the Australian Securities Exchange under the ticker OCC, has requested a trading halt on its securities. This halt is in place pending an announcement regarding a proposed capital raising. The trading halt is expected to remain until the company releases the announcement or until normal trading resumes on 17 October 2025. This move indicates a potential strategic financial maneuver by Orthocell, which could impact its market positioning and investor relations.
Orthocell Limited reported a record quarterly revenue of $3.0 million, marking the sixth consecutive quarter of growth, driven by the increasing market penetration of its nerve repair product, Remplir, in Australia and Singapore. The company is strategically expanding its commercial operations in the US and Canada, with early successes in the US market and plans for further growth in North America. The use of Remplir in nerve-sparing prostate cancer surgeries presents a significant opportunity to expand its market reach, while recent leadership appointments are expected to strengthen its operational capabilities.
Orthocell Ltd has announced its 2025 Annual General Meeting (AGM) will be held both in-person at The University Club of Western Australia and online on November 6, 2025. Shareholders are encouraged to participate and can access meeting materials and voting instructions through the company’s website and ASX platform. This meeting is crucial for stakeholders as it provides an opportunity to engage with the company’s strategic direction and governance.
Orthocell Limited reported a record revenue of $3 million for the September 2025 quarter, marking a 9.1% increase from the previous quarter. This growth is attributed to the expanding market penetration of its nerve repair product, Remplir™, particularly in Australia and Singapore. The company is poised for further revenue growth with the anticipated increase in Remplir sales in the US and Canada, supported by a strong distributor network and robust cash reserves of $27 million. The strategic expansion into these markets is expected to significantly enhance Orthocell’s industry positioning and stakeholder value.
Orthocell Limited has issued 1,563,271 fully paid ordinary shares following the cashless exercise of unlisted options, allowing immediate trading under section 708A(5) of the Corporations Act. This move reflects Orthocell’s ongoing compliance with regulatory requirements and could enhance its market liquidity, potentially benefiting stakeholders by improving the company’s financial flexibility.
Orthocell Ltd has announced the issuance of 1,563,271 new ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code OCC. This move is part of the company’s strategy to enhance its capital structure, potentially improving its market position and providing additional resources for its ongoing research and development efforts.
Orthocell Ltd has appointed its first Canadian distributor for its innovative nerve repair device, Remplir, marking a significant step in its global expansion strategy. The company has secured exclusive distributorships in Alberta and British Columbia, with further appointments expected to ensure comprehensive market coverage in Canada. The official launch will occur at the American Society for Surgery of the Hand meeting in Vancouver, with sales anticipated to begin in the December quarter. This strategic move is expected to accelerate Remplir’s international growth and improve patient outcomes, supported by Orthocell’s US-based marketing and medical education teams.
Orthocell Ltd has announced the use of its nerve repair device, Remplir, in nerve-sparing robotic-assisted radical prostatectomies (RARP) in Australia, aiming to reduce post-surgical complications such as erectile dysfunction and urinary incontinence. This development represents a significant opportunity for Orthocell to expand Remplir’s market presence, as the product is being adopted by urologists to protect and restore nerve function during prostate cancer surgeries, potentially increasing its global total addressable market.
Orthocell Limited has announced that its 2025 Annual General Meeting will be held on November 6, 2025, with the re-election of directors as a key agenda item. The closing date for director nominations is September 18, 2025. This announcement is part of Orthocell’s ongoing efforts to strengthen its governance structure as it continues to expand its market presence globally, particularly in the US with its regenerative medicine products.
Orthocell Ltd has announced interim results from its Remplir Real World Evidence study, demonstrating an 81.1% overall treatment success rate in nerve repair procedures. The study supports the US sales rollout and regulatory submissions in the EU and UK, highlighting Remplir’s effectiveness in real-world settings. The data shows significant improvements in muscle recovery and symptom relief, with no reported complications, reinforcing Remplir’s clinical success and its adoption by over 200 surgeons in more than 165 hospitals.